How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

data-driven tools
Leverage Data-Driven Tools and Local SEO for Maximum Search Engine Rankings
July 26, 2024

As businesses continue to navigate the digital landscape, data-driven tools are more crucial than ever for effective SEO strategies. Understanding and implementing the proper SEO practices can make a significant difference with evolving algorithms and competitive markets. Given that 75% of users never scroll past the first page of search results, this statistic underscores…

Read More
On-device AI
On-Device AI is Today’s Tech Innovation, Competition and Market Leadership Driver
July 26, 2024

On-device AI revolutionizes the tech landscape, making it a critical factor for industry dominance. This cutting-edge technology directly integrates advanced AI capabilities into devices, transforming consumer and enterprise applications. This shift stems from the need for improved performance, reduced latency, enhanced data privacy & security, and personalized user experiences. With advancements in neural processing…

Read More
modern supply chains
The Role of AI in Modern Supply Chains: Insights from Aaron Hatfield at Arvist
July 26, 2024

Artificial intelligence rapidly transforms modern supply chains, with companies like Arvist leading the charge. In a recent episode of Hammer Down, hosted by Mike Bush, Aaron Hatfield, the Head of Sales at Arvist, sheds light on AI’s practical applications and benefits in enhancing supply chain operations. Is AI in the supply chain a double-edged…

Read More
semiconductor manufacturing
Training New Semiconductor Manufacturing Professionals is Key to Meet Coming Domestic Manufacturing Demand
July 26, 2024

Over the past few years, the U.S. has made significant strides in semiconductor manufacturing, driven by substantial investments and strategic policies. With the CHIPS Act expected to triple domestic semiconductor manufacturing capacity by 2032, the need for a skilled workforce is more urgent than ever. This discussion explores the key question: What does the…

Read More